Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2022

Information on the total number of voting rights and shares

  • Read more about Information on the total number of voting rights and shares

Transparency declaration Nyenburgh Holding BV

  • Read more about Transparency declaration Nyenburgh Holding BV

Bone Therapeutics announces half-year results for 2022

  • Read more about Bone Therapeutics announces half-year results for 2022

Listing prospectus

  • Read more about Listing prospectus

Financial Report H1 2022

  • Read more about Financial Report H1 2022

Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook

  • Read more about Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook

Transparency notification received from Nyenburgh Holding NV

  • Read more about Transparency notification received from Nyenburgh Holding NV

Bone Therapeutics to strategically focus on lead cell therapy product ALLOB

  • Read more about Bone Therapeutics to strategically focus on lead cell therapy product ALLOB

Bone Therapeutics Secures EUR 5 Million Financing

  • Read more about Bone Therapeutics Secures EUR 5 Million Financing

Bone Therapeutics announces 2021 full year results

  • Read more about Bone Therapeutics announces 2021 full year results

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to 2022
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions